Xiaodong Jiang
Managing Partner @ Long Hill Capital
Shanghai, China
Xiaodong Jiang is a Series A investor at Long Hill Capital in Shanghai focused on Medical and Health Care. Xiaodong joined NEA in 2005 to focus on investments in the rapidly growing China markets. In December 2005, he launched New Enterprise Associates (Beijing) Ltd. and opened its Beijing and Shanghai offices. Xiaodong currently helps manage and support China related investment activities. Xiaodong's areas of interest include technology, consumer,healthcare and growth equity opportunities. Xiaodong is currently on the board of Uni-Power Group, LianLian Pay, Velo International, Shenghui Lighting, Novast Pharmaceuticals, NexChem Pharmaceuticals, HYGEIA Medical Services, New Journey Hospital Group, and PineTree Senior Care. In addition, Xiaodong has worked closely with CITIC Pharmaceuticals (acquired by Shanghai Pharma), Redbaby (acquired by SUNING), Baihe.com, LineKong, Cathay Biotech, and Availink. Xiaodong was recently honored by Entrepreneur magazine in China as one of China’s most influential venture capitalists under age 40.Prior to joining NEA, Xiaodong worked at ONStor, a storage networking start-up in marketing and business development and at IBM T.J. Watson Research Center on multimodal recognition. He was also a consultant to Hitachi on RFID market strategy. Xiaodong received a Master's degree from the University of Illinois and a bachelor's degree from Nanjing University in China. He was a doctoral candidate in computer science at University of California, Berkeley as a United Nations Fellow and a Mayfield Fellow.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Xiaodong Jiang invests in
Stages Xiaodong Jiang invests in
Countries Xiaodong Jiang invests in
Investment Focus
Industry
- Medical 8 (42%)
- Health Care 7 (37%)
- Medical Device 3 (16%)
- Robotics 2 (11%)
- Pharmaceutical 2 (11%)
Stage
- Series A 7 (37%)
- Series B 4 (21%)
- Seed 3 (16%)
- Series C 3 (16%)
- Venture - Series Unknown 1 (5%)
Country
- China 15 (79%)
- United States 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oushisheng Technology
|
Oushisheng Technology is a national high-tech company that provides complete solutions for micro-reaction flow chemistry to people all over the world. | Series B / Apr 03, 2024 | |
Aibo Medical Robot
|
Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team. | $14.1M / Series A / Jun 01, 2023 | |
Wangli Technology
|
Wangli Technology is a digital therapy technology platform for mental illness focusing on exploring the field of human brain and spirit. | $14.4M / Venture - Series Unknown / Dec 05, 2022 | |
Qingyun Technology
|
Qingyun Technology is an artificial intelligence digital marketing platform company focusing on the pharmaceutical industry. | Series C / Oct 08, 2022 | |
Shengnuo Medical
|
Sono Medical is a biomedical technology company that focuses on R&D, design, production and sales of edical equipment in the field of cardiovascular diseases. | Series A / Sep 28, 2022 | |
Lab Direct
|
Lab Direct is a developer of an online supply chain and procurement service platform that helps laboratories and research institutions to directly connect with suppliers and potential partners to get access to necessary equipment and supplies. The company was founded in 2014 and is headquartered in Shanghai, China. | $10M / Series A / Aug 26, 2022 | |
BANGBANG ROBOT
|
BANGBANG ROBOT manufactures and sells movable assistant robot for the disabled people. | $14.9M / Series B / Jun 29, 2022 | |
|
Aibo Medical Robot
|
Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team. | $18.9M / Seed / Mar 18, 2022 | |
|
Aibo Medical Robot
|
Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team. | $18.9M / Seed / Mar 18, 2022 | |
Various Technology
|
Various Technology is a provider of genetic testing and content value-added services. | $7.9M / Series A / Mar 08, 2022 | |
| See all 19 investments → | |||
Co-Investors
Alwin Capital
2 deals together
BioTrack Capital
2 deals together
CDH Investments
2 deals together
01VC
1 deal together
About Long Hill Capital
Long Hill Capital is a next generation thesis-driven venture capital firm. We invest in technology-enabled healthcare and consumer services companies which seek to massively improve health and quality of life for every Chinese.Since 2005 the founding team of Long Hill Capital have led the China investing practice for New Enterprise Associates(NEA), a global investment firm with over $17 billion in committed capital. They are joined by an experienced team of investment and operations professionals from such firms as Matrix Partners China and Morningside VC. Together the Long Hill Capital team have over 30 years of China venture capital experience and over 15 years of senior operating experience at some of China’s most successful technology and healthcare companies including Alibaba, Huawei and Ping’an Good Doctor.Over the course of their venture capital careers, the Long Hill Capital team have invested in such industry leading companies as CITIC Pharmaceutical, WeDoctor, Hygeia Medical Services, GST Clinics, LineKong, LianLian Pay, Ele.Me, TheBeastShop and more.
Long Hill Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hangcheng Sun
Investment Director
|
|||
Song Mei
Vice President
|
|||
|
Xiaodong Jiang
Managing Partner
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Xiaodong Jiang invest in?
Xiaodong Jiang invests primarily in Medical, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Xiaodong Jiang last invest?
The most recent investment recorded for Xiaodong Jiang closed in Apr 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
